Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

82 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Arteriosclerosis is a dynamic inflammatory disorder. Recently, FDG-PET CT is emerging diagnostic tool of non-invasive technique to detect vulnerable atherosclerotic plaque. And there are arising evidence that sRAGE(soluble Receptor for Advanced glycation End Product) is correlated with metabolic risk. So the investigators will investigate association between sRAGE and FDG-PET uptake in large artery in healthy patient.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)

NCT01150006

Atherosclerosis

COMPLETED

Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation

NCT01100671

Atherosclerosis

COMPLETED

PET Imaging of Fibroblast Activation in Atherosclerosis

NCT06280287

Atherosclerosis

RECRUITING

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

NCT01254591

Breast Cancer Colorectal Cancer Esophageal Cancer +2 more

UNKNOWN NA

PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

NCT00742352

Atherosclerosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

sRAGE Level SUV and TBR Levels in FDG PET

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 DM, Healthy control

Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.

No interventions assigned to this group

Type 2 DM, Heatlhy control

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis od type 2 DM

Exclusion Criteria

* Type 1 DM
* Gestational Diabetes
* Severe Liver or Renal disease
* Diagnosis of cancer
* Trauma
* Acute infection or inflammatory disease
* Acute vasculitis or history of vasculitis
* Pregnant or Lactating women
* Dyslipidemia(active state)
* Cardiovascular disease or history of CVD
* Chronic obstructive pulmonary disease
* Any patient by judge of investigator

Minimum Eligible Age

16 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No